Hanmi R&D becomes stronger through cooperation with partners.
- efocipegtrutide (LAPSTriple agonist)
- sonefpeglutide (LAPSGLP-2 analog)
- efpegerglucagon (LAPSGlucagon analog)
- HM97662 (EZH1/2 inhibitor)
- BH3120 (PD-L1/4-1BB BsAb)
- HM15275 (LA-GLP/GIP/GCG)
- HM16390 (LAPSIL-2 analog)
- HM17321 (LA-UCN2)
- HM101207 (SOS1 inhibitor)
- LAPS Glucagon Combo
HM101207 (SOS1 inhibitor)
Oncology
Preclinical
Overview
A SOS1 inhibitor demonstrating antitumor activity
against KRAS-mutant cancers
Description
against KRAS-mutant cancers
RAS is the most mutated oncogene in various human cancers. Son of sevenless homolog 1 (SOS1) is a guanine nucleotide exchange factor (GEF) on RAS that promotes the exchange of bound GDP to GTP.
SOS1 protein is a promising therapeutic target in RAS-mutant and other RTK-altered cancers. A novel SOS1 inhibitor, HM101207, potently inhibits interaction of KRAS-SOS1 and has improved selectivity and drug-drug interaction (DDI) profiles compared to other candidates.
SOS1 protein is a promising therapeutic target in RAS-mutant and other RTK-altered cancers. A novel SOS1 inhibitor, HM101207, potently inhibits interaction of KRAS-SOS1 and has improved selectivity and drug-drug interaction (DDI) profiles compared to other candidates.
Antitumor activities
- Potent inhibition of p-ERK and good antitumor activity regardless of KRAS mutation types and tumor types
- Very low potential of CYP enzyme inhibition, enabling to apply combination with various targeted agents
- Non-inferior to superior potency on antitumor activity to competitors when combined with KRAS G12C inhibitors or MEK inhibitors in various KRAS-driven tumor models
Clinical Development
- IND enabling GLP-toxicity studies are planned in 2H 2025.
Publications